Pasted below are some good comments I’m linking to that give a good status synopsis for Bioelectronics World.
To add to the comments below by an art2426
The stock (BIEL) spiked since a couple of their products got cleared for OTC (Over the counter) by the FDA. Backed off a bit, but this isn’t over. News drives this stock, and I cannot stress this enough–FDA clearance opens up a lot of vistas for news, such as licensing deals, partnerships, new 510 K applications that now have a previously approved medical device to use as a precedent, and Buyouts.
“>>>Whatever happens, it is going to be nothing but positive going forward. This company reached its ultimate low point before they were finally granted OTC clearance. We should simply relax and watch. This is a real company with a real product with real patents and with real FDA OTC clearance for the first time ever in the USA in this technology domain. The FDA created this domain space OTC because of Biel.<<<
All this other talk and disagreement is just rhetoric. We the stockholders just received something that was long sought and there is NO WAY this can be twisted and turned, ignored or argued about —- IT IS A VERY POSITIVE EVENT. One that in no way can be construed as NOT positive. Argue all you want about share structure etc. Do you not realize what has just happened! A small stinky pinky got the notice of the all powerful FDA and the all powerful FDA just confirmed that 2 of their products, after EXTENSIVE SCRUTINY, IS beneficial, safe and efficient in pain management for specific parts of the body. With this determination it is obvious that other uses and future products of this company will follow (back patch next?). Breaking through and convincing the FDA on the first product is ALWAYS the most difficult, as we have witnessed with this LONG process leading up to this approval. Can anyone really believe that the back patch will not be OK’d? That many more future products from this company for various other ailments will not be forthcoming? All of this will result in continual spikes in stock price, further strengthening the perception and validity of this company and its products.